•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements with a strategic business partner in Egypt and Pakistan pharmaceutical company Searle Co Ltd. These agreements grant local rights to Mabwell’s denosumab biosimilars, MAILISHU and 9MW0321. Denosumab Biosimilars and Their Impact on Fracture Risk ReductionDenosumab,…